Background: Hepatitis C virus [HCV] infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet [ombitasvir/ paritaprevir/ritonavir] in combination with ribavirin was effective and generally well tolerated in treatment of chronic HCV infected patients with end stage renal disease [ESRD] on hemodialysis. However, limited published data are known about the usefulness of this regimen for treatment of HCV patients with ESRD on hemodialysis. Aim of the work: The aim of this study was to evaluate the safety and efficacy of treatment regimen of ombitasvir [OBV] 25 mg /paritaprevir [PTV] 150 mg /ritonavir [RTV] 100 mg plus generic ribavirin [RBV] 200 mg in Egyptian HCV-infected naive patients with ESRD on regular hemodialysis. Patients and methods: A prospective cohort study involved 40 chronic HCV on regular hemodialysis patients, who were eligible for treatment with combined oral antiviral therapy. Results: The results showed that thirty-five patients [35/40[87.5%]] completed 12 weeks of HCV therapy; they had a virological response at end of therapy and sustained virological response. Anemia was the main observed side effect which lead to discontinuation of the treatment in five patients [12.2%]. As these patients were not responding to anemia correction measures [blood transfusion, erythropoietin-stimulating agents, and modification of RBV dose]. Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD on regular hemodialysis. This is an open access article under the Creative Commons license [CC BY] [https://creativecommons.org/licenses/by/2.0/] Please cite this article as El-Gendy NA, EL-Raey FM, Nassibi SA, Elsadany N. Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis. IJMA 2020; 2[1]: 313-319.
INTRODUCTION
Hepatitis C virus infection prevalence among hemodialysis [HD] patients ranges from 5% to approximately 60% in different countries [1, 2] .
Increased risk of morbidity and mortality in these patients favor the treatment of HCV infection [3, 4] .
Eradication of HCV help to reduce its prevalence and risk of nosocomial transmission in HD units [5, 6] .
Early experience of combined therapy with pegylated interferon and ribavirin in these patients showed 40% sustained virological response with very poor tolerance, leading to withdrawal of this regimen in more than 1/3 of patients [7] .
Although these limitations, this combination demonstrated the durability of virological response even post renal transplantation [8] .
Introducing of direct-acting antiviral drugs [DAAs] in treatment of HCV infection have led to a sustained virological response after 12 weeks of treatment [SVR12] in more than 90%-95% of the patients with improved tolerance. Fortunately, the NS5A inhibitor ombitasvir, the NS3/4A inhibitor paritaprevir and ritonavir are not excreted by the kidneys and do not need dose adjustment in severe CKD or in HD patients [9, 10] .
Observational studies from Europe and the United States reported the use of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ±ribavirin in treatment of HCV infection in end stage renal disease [ESRD] [11, 12] .
An Egyptian study found that, ombitasvir/ paritaprevir/ritonavir in combination with ribavirin was generally well tolerated in treatment of HCV patients without cirrhosis or with compensated cirrhosis with 97 and 93 % SVR12 respectively [13] .
AIM OF THE WORK
The aim of this study was to evaluate the safety and efficacy of a combination oral antiviral therapy [ombitasvir 25 mg /paritaprevir 150 mg/ ritonavir 100 mg] plus generic ribavirin [200 mg] in treatment of chronic HCV-infected patients with end stage renal disease [ESRD] on regular hemodialysis. Fib-4 score was calculated for each patient as the following:
PATIENTS AND METHODS
.Where Fib4 score < 1.45 = F0-F1 and Fib4 score > 3.25 = F3-F4 as illustrated by Martinez et al. [15] .
Patients were on regular hemodialysis, for more than 3 months, 3 sessions /week, 4h/session, bicarbonate-based dialysate. Comparing groups were done by using Independent t-test and One-Way ANOVA test followed by post hoc test analysis using LSD.
The confidence interval was set to 95% and the margin of error accepted was set to 5%. The pvalue was considered non-significant [NS] at the level of > 0.05, significant at the level of <0.05 and highly significant at the level of <0.001. 
RESULTS

Forty
DISCUSSION
Elimination of Hepatitis C virus [HCV] infection in patients with end-stage renal disease [ESRD] or requiring hemodialysis decreases liver disease progression and liver-related morbidity/mortality [16] . Also, reduces the risk of cardiovascular disease, diabetes and extra-hepatic cancers and improves their quality of life [17] . The access to new DAAs that mainly metabolized in the liver with minimal renal elimination as the ombitasvir,, and ritonavir-boosted paritaprevir [OBV/PTV/RTV] is available in a fixeddose combination pill [18] . This combination is requiring no dose adjustment in patients with renal impairment. However, for maximum virological response ribavirin [RBV] is added to this combination in patients with genotype 1a [19] .
Forty Egyptian naïve patients with ESRD were received combination of ombitasvir [25mg] / paritaprevir [150 mg]/ritonavir [100 mg], plus generic ribavirin [200 mg] for 12 weeks. There were 87.5 % of the patients completed 12 weeks of HCV therapy. Such patients showed 100% a sustained virological response. In Japan, 10 chronic HCV patients genotype 1b on regular hemodialysis received OBV/PTV/RTV combination therapy. Eight of them [80%] completed 12 weeks therapy and achieved SVR12, while, two [20%] patients discontinued the drugs because of its side effects [20] . More adherent to the therapy and less withdrawal rate were reported by Gómez et al. [11] and Pockros et al. [21] Anemia was the main side effect occurred during the course of treatment in the current study. Impaired renal clearance increases the potential risk of ribavirin-induced hemolytic anemia [22] . Because of the distribution of RBV occurs mainly outside the plasma [primarily intracellular], since a very small amount of the drug in the body is available to be eliminated by dialysis [23] . Safety and efficacy of the RBV-free regimen ombitasvir/ paritaprevir/ ritonavir ± dasabuvir in patients with ESRD [on hemodialysis] with HCV genotype 1a or 4 studied in RUBY-II clinical trial, which enrolled 18 treatment-naïve and non-cirrhotic adults patients. The overall SVR12 was 94% [17/18] ; one patient discontinued the study to undergo an elective renal transplantation [24] .This combination well tolerated with no serious side effect. The authors concluded that RBV may not be necessary in some genotype 1a-or 4-infected patients with ESRD [on hemodialysis] [24] . Conclusion: OBV/PTV/RTV plus Ribavirin was an effective therapy of Egyptian naïve chronic HCV patients with end stage renal disease on regular hemodialysis.
Recommendation: Use OBV/PTV/RTV without Ribavirin in treatment of chronic HCV patients with end stage renal disease on regular hemodialysis to avoid resistant anemia and improve patients' adherence to treatment.
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